NCT00988260已完成2 期
A Phase II Bridging Trial of Org 37462
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 266
- 主要终点
- Intrauterine vital pregnancy rate
研究概览
简要总结
The purpose of this study is to find the optimal dose of Org 37462 for Japanese females undergoing controlled ovarian stimulation for in vitro fertilization intracytoplasmic sperm injection (IVF-ICSI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 39 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Japanese females of infertile married couples with an indication for COH and IVF with or without ICSI.
- •At least 20 but not older than 39 years of age at the time of screening.
- •A body mass index (BMI) between 18 and
- •Normal menstrual cycle with a range of 24-35 days and an intra-individual variation of plus or minus 3 days (but never outside the 24-35 days range).
- •Infertile couple that is willing to give written informed consent.
- •Determination of inclusion criteria
- •is determined in view of the planned therapeutic indication.
- •is determined based on ethical considerations for the subjects (not younger than 20) and also in view of the planned therapeutic indication (not older than 39)
- •is determined to avoid bias on the effects of Org 37462 by emaciation and obesity.
- •is determined to avoid the influences of endogenous hormones considering the purpose of this trial to select the minimal effective dose of Org
- •is determined from the ethical consideration of the subjects.
排除标准
- •History of/or current endocrine abnormality such as polycystic ovary syndrome (PCOS) or polycystic ovaries according to USS, (treated) hyperprolactinemia or evidence of ovarian dysfunction.
- •History of non- or low- ovarian response to FSH/hMG treatment.
- •Abnormal cervical smear according to the Papanicolaou (>= class III) or Bethesda (>= CIN 1) scale.
- •History of/or current Type I hypersensitivity (urticaria, eczema, hay fever, asthma), meaning that the subject is using prescribed medication on a regular basis or that the subjects history is prohibitive for Org 37462 treatment according to the clinical opinion of the sub-investigator.
- •Any hormone value outside the reference range during the early follicular phase as measured by the central laboratory (Japan) [FSH, LH, E2, P, androstenedione (AD), dehydroepiandrosterone sulphate (DHEAS), testosterone (T), thyroid stimulating hormone (TSH) and prolactin].
- •Any clinically significant abnormal laboratory value of the central laboratory (Japan) (routine hematology, blood biochemistry).
- •Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation of both ovaries, thus excluding subjects with only one ovary.
- •Contra-indications for the use of gonadotropins i.e.,
- •tumors of ovary, breast, uterus, pituitary or hypothalamus.
- •pregnancy or lactation.
- •undiagnosed vaginal bleeding.
- •hypersensitivity to any of the substances in recFSH (FSH, sucrose, sodium citrate, polysorbate 20 and sodium chloride, L-methionine).
- •ovarian cysts or enlarged ovaries not related to PCOS.
- •malformation of the sexual organs incompatible with pregnancy.
- •fibroid tumors of the uterus incompatible with pregnancy.
- •Use of hormonal preparations within 1 month prior to screening.
- •Hypertension (systolic blood pressure >150 mm Hg and/or diastolic blood pressure >90 mm Hg) or treated hypertension.
- •Epilepsia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease.
- •Administration of investigational drugs within 3 months prior to screening.
研究组 & 干预措施
Ganirelix 0.125 mg
Experimental
干预措施: Ganirelix (Drug)
Ganirelix 0.25 mg
Experimental
干预措施: Ganirelix (Drug)
Ganirelix 0.5 mg
Experimental
干预措施: Ganirelix (Drug)
结局指标
主要结局
Intrauterine vital pregnancy rate
时间窗: 5-6 weeks after embryo transfer (ET)
Incidence of Luteinizing Hormone (LH) rise
时间窗: During treatment (1-14 days)
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05488314Janssen Research & Development, LLC57
已完成
1 期
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT06532032Janssen Research & Development, LLC12
进行中（未招募）
1 期
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05908734Janssen Research & Development, LLC71
已完成
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid CancersNeoplasmNCT03547037Janssen Pharmaceutical K.K.22
已完成
2 期
Biological Sling Allograft (UVT) for the Treatment of Urinary Incontinence in Women Presenting With Synthetic Sling ComplicationsFemale Stress IncontinenceStress Urinary IncontinenceNCT05207189TBF Genie Tissulaire16